• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Progenitor Labs secures $5.8M to progress regenerative medicine platform

Progenitor Labs secures $5.8M to progress regenerative medicine platform

March 11, 2013
CenterWatch Staff

Progenitor Labs, a regenerative medicine company, has raised $5.8 million in seed financing from the U.K. Fund of SR One, GlaxoSmithKline's independent corporate healthcare venture capital fund.

Progenitor develops drugs to regenerate specific tissues of the human body in response to injury, disease or aging. Development of small molecules in regenerative medicine has potential technical, commercial and regulatory advantages over cell therapies. The financing will enable the company to discover small molecule drugs for a number of serious diseases.

Progenitor uses CombiCultÒ combinatorial stem cell technology to produce synthetic adult progenitor cells that resemble those lying dormant in a patient’s target tissue. Pharmaceutical drug screens can then be performed to discover compounds that instruct the progenitor cells to generate terminally differentiated cells, thereby restoring organ function. Whereas most currently available drugs treat the symptoms of illness, drugs that regenerate diseased organs will address the root cause of disease.

Progenitor will be based at Stevenage Bioscience Catalyst (SBC), the U.K.' s first open innovation bioscience campus. Concurrent with the financing, Progenitor has also entered into an agreement with Scinovo, GSK’s scientific consultancy and technical support model, which includes access to GSK scientists with a proven track record of bringing compounds from discovery through to launch.

“We are delighted to have attracted top tier venture financing and to have put in place an R&D infrastructure capable of delivering drugs that have the potential to transform regenerative medicine and future healthcare,” said Dr. Yen Choo, founder and CEO of Progenitor Labs.

David Phillips and Matthew Foy, partners at SR One, will join Progenitor’s board of directors.

Phillips  said, “We believe that Progenitor’s ground-breaking technology, combined with SBC’s open innovation model and drug discovery and development expertise of GSK’s Scinovo, is a paradigm for future U.K. biotech success stories.”

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing